New drug IM-1021 enters human trials for advanced cancers
NCT ID NCT06823167
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 44 times
Summary
This early-stage study tests a new drug called IM-1021 in about 117 adults with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants will receive the drug and be closely monitored for side effects and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City Of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gabrail Cancer Center
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Norton Healthcare
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
START - Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-••••
-
Sarah Cannon Research Institute - Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University Medical Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.